J.C. Penney Takes Poison Pill To Dissuade Future Ackmans

Aug 23 2013 | 5:28am ET

J.C. Penney Co. wants to make sure it doesn’t have another William Ackman to deal with.

The retailer, recently embroiled in a very public fight with the Pershing Square Capital Management chief, its largest shareholder, adopted a poison pill that makes it very difficult and expensive to buy more than 10% of the company. The shareholder rights plan will expire in a year and doesn’t cover Pershing Square—as long as any increase in its stake doesn’t violate existing agreements with the company.

The plan will “protect against potential future use of coercive or abusive takeover techniques,” J.C. Penney said.

Pershing Square owns nearly 18% of J.C. Penney. Ackman resigned from the company’s board last week after publicly calling for the replacement of the company’s chairman and interim CEO.

Following his exit, Ackman said he would consider selling off his stake in J.C. Penney. The poison pill makes it unlikely that another activist would be able to take his place.


In Depth

Israeli Hedge Fund Harnesses Big Data

Jul 28 2014 | 8:10am ET

Apica Green is a multi-million dollar Israeli hedge fund that is based in Tel Aviv...

Lifestyle

David Yarrow On Growing His Hedge Fund And Shooting The Animals And People Of Africa - As A Photographer

Jul 23 2014 | 6:44am ET

While he’s always been a photographer, recent expeditions to Iceland, Ethiopia...

Guest Contributor

The Truth About Track Record Portability

Jul 24 2014 | 5:55am ET

The number of private funds converting to mutual funds has increased significantly...

 

Sponsored Content

    Northern Trust Helps Hedge Funds Navigate Derivatives Regulations

    Jul 8 2014 | 10:48am ET

    The surge in derivatives regulation is among the most complex challenges facing the financial services industry today. Northern Trust’s Joshua Satten recently spoke with FINalternatives to share insights into the challenges presented by new regulation and explore how the industry is responding. Read more…

Publisher's Note